4CPS-166 Association between immune-related effects and effectiveness of first-line pembrolizumab in advanced non-small-cell lung cancer

Background and importancePembrolizumab in monotherapy (in patients with PD-L1 expression ≥50%) or in combination with platinum-based chemotherapy (CT) (PDL-1

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2022-03, Vol.29 (Suppl 1), p.A84-A85
Main Authors: Martínez Díaz, C, Fenix Caballero, S, Cercos Lleti, AC, Gil Sierra, MD, Alegre del Rey, EJ
Format: Article
Language:English
Subjects:
Cancer therapies
Conflicts of interest
Immunotherapy
Lung cancer
Monoclonal antibodies
Population
Section 4: Clinical pharmacy services
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and importancePembrolizumab in monotherapy (in patients with PD-L1 expression ≥50%) or in combination with platinum-based chemotherapy (CT) (PDL-1
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2022-eahp.177